Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-04-18
1997-09-30
Bond, Robert T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514213, 514312, 514418, 540461, 540523, 546158, 548486, A61K 3155, C07D20934, C07D215227, C07D22316
Patent
active
056725965
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
Growth hormone, which is secreted from the pituitary, stimulates growth of all tissues of the body that are capable of growing. In addition, growth hormone is known to have the following basic effects on the metabolic process of the body: energy.
A deficiency in growth hormone secretion can result in various medical disorders, such as dwarfism.
Various ways are known to release growth hormone. For example, chemicals such as arginine, L-3,4-dihydroxyphenylalanine (L-DOPA), glucagon, vasopressin, and insulin induced hypoglycemia, as well as activities such as sleep and exercise, indirectly cause growth hormone to be released from the pituitary by acting in some fashion on the hypothalamus perhaps either to decrease somatostatin secretion or to increase the secretion of the known secretagogue growth hormone releasing factor (GRF) or an unknown endogenous growth hormone-releasing hormone or all of these.
In cases where increased levels of growth hormone were desired, the problem was generally solved by providing exogenous growth hormone or by administering an agent which stimulated growth hormone production and/or release. In either case the peptidyl nature of the compound necessitated that it be administered by injection. Initially the source of growth hormone was the extraction of the pituitary glands of cadavers. This resulted in a very expensive product and carried with it the risk that a disease associated with the source of the pituitary gland could be transmitted to the recipient of the growth hormone. Recently, recombinant growth hormone has become available which, while no longer carrying any risk of disease transmission, is still a very expensive product which must be given by injection or by a nasal spray.
Other compounds have been developed which stimulate the release of endogenous growth hormone such as analogous peptidyl compounds related to GRF or the peptides of U.S. Pat. No. 4,411,890. These peptides, while considerably smaller than growth hormones are still susceptible to various proteases. As with most peptides, their potential for oral bioavailability is low. The instant compounds are non-peptidyl agents for promoting the release of growth hormone which may be administered parenterally, nasally or by the oral route.
SUMMARY OF THE INVENTION
The instant invention covers certain benzo-fused lactam compounds which have the ability to stimulate the release of natural or endogenous growth hormone. The compounds thus have the ability to be used to treat conditions which require the stimulation of growth hormone production or secretion such as in humans with a deficiency of natural growth hormone or in animals used for food production where the stimulation of growth hormone will result in a larger, more productive animal. Thus, it is an object of the instant invention to describe the benzo-fused lactam compounds. It is a further object of this invention to describe procedures for the preparation of such compounds. A still further object is to describe the use of such compounds to increase the secretion of growth hormone in humans and animals. A still further object of this invention is to describe compositions containing the benzo-fused lactam compounds for the use of treating humans and animals so as to increase the level of growth hormone secretions. Further objects will become apparent from a reading of the following description.
DESCRIPTION OF THE INVENTION
The novel benzo-fused lactams of the instant invention are best described in the following structural formula I: ##STR1## where L is ##STR2## n is 0 or 1; p is 0 to 3; ##STR3## m is 0 to 2; R.sup.1, R.sup.2, R.sup.1a, R.sup.2a, R.sup.1b and R.sup.2b are independently hydrogen, halogen, C.sub.1 -C.sub.7 alkyl, C.sub.1 -C.sub.3 perfluoroalkyl, C.sub.1 -C.sub.3 perfluoroalkoxy, --S(O).sub.m R.sup.7a, cyano, nitro, R.sup.7b O(CH.sub.2).sub.v --, R.sup.7b COO(CH.sub.2).sub.v --, R.sup.7b OCO(CH.sub.2).sub.v, R.sup.4 R.sup.5 N(CH.sub.2).sub.v --, R.sup.7b CON(R.sup.4)(CH.sub.2).sub.v --, R.sup.4 R.sup.5 NCO(CH.s
REFERENCES:
patent: 3239345 (1966-03-01), Hodge et al.
patent: 4036979 (1977-07-01), Asato
patent: 4411890 (1983-10-01), Momany
patent: 4692522 (1987-09-01), Parsons et al.
patent: 5206235 (1993-04-01), Fisher et al.
patent: 5283241 (1994-02-01), Bochis et al.
patent: 5284841 (1994-02-01), Chu et al.
patent: 5310737 (1994-05-01), Fisher et al.
patent: 5317017 (1994-05-01), Ok et al.
patent: 5374721 (1994-12-01), Schoen et al.
patent: 5430144 (1995-07-01), Schoen et al.
patent: 5434261 (1995-07-01), Schoen et al.
patent: 5438136 (1995-08-01), Devita et al.
Slade, et al., J. Med. Chem, 28, 1517-1521 (1985), "Angiotensin Converting Enzyme Inhibitors . . . ".
Huang, et al., Synthesis, 10, 851 (1984), "Synthesis of 3-Oxo-3,4-dihydro-2H-1,4-benzoxazines . . . ".
Stewart, Australia J. Chem., 33, 633-640 (1980), "Synthesis of L-Kynurenine Peptides . . . ".
Still, et al., J. Org. Chem., 43, 2923 (1978), "Rapid Chromatographic Technique . . . ".
Parsons, et al., Med. Chem., 32, 1681-1685 (1989), "Cholecystokinin Antagonists . . . ".
Jones, et al., J. Chem. Soc. c, 2176-2181 (1969), "N-Alkylaminoalkyl Derivatives of some Hexahydrobenzazocines".
Davis, et al., Arch. Biochem. Biophys, 102, 48-51 (1963), "The Synthesis . . . of o-Aminophenylalanine . . . ".
Wattley, et al., J. Med. Chem., 28, 1511-1516 (1985), "Synthesis . . . of (Carboxyalkyl) amino-substituted Lactam Inhibitors . . . ".
Bochis Richard
Devita Robert
Schoen William
Wyvratt Matthew
Bond Robert T.
Merck & Co. , Inc.
Rose David L.
Thies J. Eric
LandOfFree
Benzo-fused lactams promote release of growth hormone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzo-fused lactams promote release of growth hormone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzo-fused lactams promote release of growth hormone will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2256754